step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Two-year effects of in adults with overweight or obesity: the 5 Semaglutide for the treatment of
Description
It reduces body weight
The medication is not recommended for those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Its also possible that GLP-1 receptor agonists may not be the optimal weight management intervention for you
00182-7/asset/2f41891b-f9ef-4082-bc88-bb8d303f3603/main.assets/gr2_lrg.jpg)
That means youre less likely to get a sharp spike and crash in blood sugar
As you can see, you are more likely to develop nutrition deficiencies when these two weight loss methods are combined
This suggests a possible risk in humans, particularly thyroid C-cell cancers
00226-8/asset/fd74d5b9-b94f-420a-ba3e-9f0baf1be2f1/main.assets/gr2_lrg.jpg)
